Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL Biopharmaceuticals has initiated a phase Ia clinical trial of its drug XTL-6865 for the treatment of chronic hepatitis C virus, and prevention of re-infection with the disease following a liver transplant.
Subscribe to our email newsletter
This trial is being conducted under an investigational new drug application, filed with the Food and Drug Administration in April this year. The trial is a multi-center trial and will be conducted in the US and Israel.
The compound is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. A single antibody version of this product was tested in a pilot clinical program that included both phase I and phase II clinical trials and provided preliminary evidence of anti-viral activity in humans.
“Earlier this year, we set the initiation of clinical trials with XTL-6865 as a significant corporate milestone for 2005. We are very pleased to have accomplished this milestone, and look forward to the further advancement of this important product in our HCV portfolio,” commented Michael Weiss, XTLbio’s chairman.